SEC Form 4 · accession 0001567619-19-001176
BIOMARIN PHARMACEUTICAL INC · BMRN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jean Jacques Bienaime
Officer — Chief Executive Officer · Director
Period of report
Jan 14, 2019
Accepted (ET)
Jan 15, 2019 · 7:43 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001048477
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 14, 2019 | M | 4,000 | $14.39 | A | 292,290 | D | |
| Common StockF1 | Jan 14, 2019 | S | 4,000 | $93.79 | D | 288,290 | D | |
| Common Stock | holding | — | — | — | 181,501 | I | Shares held by Jean-Jacques Bienaime Family Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy Common Stock)F1,F2 | $14.39 | Jan 14, 2019 | M | 4,000 | D | Nov 12, 2009 | May 11, 2019 | Common Stock | 4,000 | 76,000 | D |
Explanation of responses
- F1Trade made pursuant to a 10b5-1 plan executed on September 10, 2018.
- F2Reflects the number of options outstanding after the transactions from this specific stock option grant.